Literature DB >> 1837635

Immunization of pigs with a purified Shiga-like toxin II variant toxoid.

D L MacLeod1, C L Gyles.   

Abstract

Passive transfer of neutralizing antibodies and active immunization with a toxoid of purified Shiga-like toxin II variant (SLT-IIv, edema disease toxin) were used to protect pigs against challenge with SLT-IIv. Six 6-week-old pigs were passively immunized by intraperitoneal administration of an immunoglobulin preparation from porcine antiserum against purified SLT-IIv. Six 6-week-old pigs and twelve 2-week-old pigs were actively immunized by two intramuscular injections of 25 micrograms of SLT-IIv toxoid given 2 weeks apart. The 24 immunized pigs and an equal number of age-matched unimmunized control pigs were all challenged by intravenous injection of purified SLT-IIv (6 ng/kg body weight). The six passively immunized pigs acquired neutralizing SLT-IIv antibody titers of 1280 or 2560 and the 18 actively immunized pigs mounted a serum immune response with toxin neutralizing titers ranging from 128 to 10,240. All 24 immunized pigs survived the challenge but nine pigs with the lowest titers showed mild clinical signs of edema disease. All 24 control pigs died within 30 hours of challenge.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1837635     DOI: 10.1016/0378-1135(91)90138-6

Source DB:  PubMed          Journal:  Vet Microbiol        ISSN: 0378-1135            Impact factor:   3.293


  16 in total

1.  Protection against Shiga toxin 1 challenge by immunization of mice with purified mutant Shiga toxin 1.

Authors:  Satoshi Ishikawa; Kazuyoshi Kawahara; Yutaka Kagami; Yasunori Isshiki; Aki Kaneko; Hidenori Matsui; Nobuhiko Okada; Hirofumi Danbara
Journal:  Infect Immun       Date:  2003-06       Impact factor: 3.441

2.  Prevention of edema disease in pigs by vaccination with verotoxin 2e toxoid.

Authors:  M Johansen; L O Andresen; S E Jorsal; L K Thomsen; T E Waddell; C L Gyles
Journal:  Can J Vet Res       Date:  1997-10       Impact factor: 1.310

3.  Neutralizing antibodies to Shiga toxin type 2 (Stx2) reduce colonization of mice by Stx2-expressing Escherichia coli O157:H7.

Authors:  Krystle L Mohawk; Angela R Melton-Celsa; Cory M Robinson; Alison D O'Brien
Journal:  Vaccine       Date:  2010-05-14       Impact factor: 3.641

4.  Effectiveness of egg yolk antibody against shiga toxin II variant toxicity in vitro and in vivo.

Authors:  Yufei Feng; Wenxin Liu; Dongfang Shi
Journal:  Curr Microbiol       Date:  2013-05-21       Impact factor: 2.188

5.  Prevention of edema disease in pigs by passive immunization.

Authors:  M Johansen; L O Andresen; L K Thomsen; M E Busch; H Wachmann; S E Jorsal; C L Gyles
Journal:  Can J Vet Res       Date:  2000-01       Impact factor: 1.310

6.  Localization of intravenously administered verocytotoxins (Shiga-like toxins) 1 and 2 in rabbits immunized with homologous and heterologous toxoids and toxin subunits.

Authors:  M Bielaszewska; I Clarke; M A Karmali; M Petric
Journal:  Infect Immun       Date:  1997-07       Impact factor: 3.441

7.  Toxicity and immunogenicity of a verotoxin 1 mutant with reduced globotriaosylceramide receptor binding in rabbits.

Authors:  D J Bast; J L Brunton; M A Karmali; S E Richardson
Journal:  Infect Immun       Date:  1997-06       Impact factor: 3.441

8.  Protection of piglets against Edema disease by maternal immunization with Stx2e toxoid.

Authors:  Thi Kim Nguyen Oanh; Viet Khong Nguyen; Henri De Greve; Bruno Maria Goddeeris
Journal:  Infect Immun       Date:  2011-11-14       Impact factor: 3.441

9.  Binding of shiga toxin 2e to porcine erythrocytes in vivo and in vitro.

Authors:  Ilze Matise; Nancy A Cornick; James E Samuel; Harley W Moon
Journal:  Infect Immun       Date:  2003-09       Impact factor: 3.441

10.  Expression of A and B subunits of Shiga-like toxin II as fusions with glutathione S-transferase and their potential for use in seroepidemiology.

Authors:  F Gunzer; H Karch
Journal:  J Clin Microbiol       Date:  1993-10       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.